This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Nanotechnol. 2026, 17, 139–158, doi:10.3762/bjnano.17.9
Figure 1: Fractograms from the qualitative evaluation using AF4–UV–MALS–DLS of the native formulations a) NLb...
Figure 2: Comparative representation of the UV signal and z-average diameter of NLb1 after a) 1 h incubation ...
Figure 3: Comparative representation of the UV signal and z-average diameter of NLb2 after a) 1 h incubation ...
Figure 4: Comparative representation of the UV signal and z-average diameter of NLb0 after a) 1 h incubation ...
Figure 5: High-resolution automated electrophoresis band representation of a) NLb1 and NLb2 after 1 and 4 h i...
Figure 6: Cell uptake of NLs (10 μg/mL) in a) hCMEC/D3 cells and b) SH-SY5Y after a 2 h incubation at 4 °C wi...
Figure 7: Fluorescent microscopy (Nile-red channel used) showing internalization in live hCMEC/D3 cells of a)...
Figure 8: Fluorescent microscopy (Nile-red channel used) showing internalization in SH-SY5Y cells of a) NLb0,...
Figure 9: Representation of a) NLb0, b) NLb1, and c) NLb2 in live SH-SY5Y cells (4 h) by fluorescent microsco...
Figure 10: Confocal microscopy showing internalization and distribution of a) NLb0, b) NLb1, and c) NLb2 in hC...
Beilstein J. Nanotechnol. 2023, 14, 240–261, doi:10.3762/bjnano.14.23
Figure 1: Examples of combinatorial therapy for (left) EGFR-dependent and (right) EGFR-independent TKI resist...
Figure 2: (A) Gefitinib-loaded gelatin-A NPs functionalized with a cetuximab-siRNA conjugate (Ab-SiRNA-GelGEF...
Figure 3: Nanotools for reversal of EGFR TKI resistance by RNAi. Favorable cell internalization was mediated ...
Beilstein J. Nanotechnol. 2021, 12, 375–401, doi:10.3762/bjnano.12.31
Figure 1: Hypothetical mechanisms of extravasation of NDDSs into the BM stroma. The nanoscale carrier could i...
Figure 2: Schematic representation of a polyrotaxane nanoconstruct bearing surface-oriented PTK7 aptamers for...
Figure 3: Wool-like hollow polycaprolactone (PCL) NDDS for the sequential co-delivery of imatinib mesylate (I...
Figure 4: EGFR targeting strategies using “non-conventional” ligands. (a) Heparin nanoparticles with surface-...
Figure 5: A multifunctional hyaluronan nanogel targeting EGFR and CD44. The binding of hyaluronan residues an...
Figure 6: HA-functionalized NDDS with multimodal targeting capabilities. (a) HA–paclitaxel (PTX) complex and ...